PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Anti-CD38 Quadruplets Lead MRD Rankings; Transplant Benefit Remains Unproven

daratumumabisatuximabanti-CD38 monoclonal antibodiescarfilzomibbortezomiblenalidomidenewly diagnosed multiple myelomameasurable residual diseasesustained MRDautologous stem cell transplantationnetwork meta-analysissystematic reviewquadruplet therapyoncology pharmacy Oncology

Background Information

Anti-CD38 regimens excel in achieving MRD negativity in myeloma.

The study evaluates the effectiveness of anti-CD38 monoclonal antibody-based regimens in newly diagnosed multiple myeloma. Anti-CD38-KRd regimens showed the highest MRD negativity, but adding ASCT did not significantly change outcomes. These findings suggest that anti-CD38 regimens are effective, but the role of ASCT may be limited. More data is needed for definitive conclusions. Anti-CD38-based treatments significantly improve MRD negativity in multiple myeloma.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Caridà G, Scalise L, Mosca A, De Fazio L, Costa M, Molica M, Rossi M

Citation: Caridà G, Scalise L, Mosca A, et al. Achievement and Persistence of MRD Negativity with Anti-CD38-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta-Analysis. Cancers. 2026;18(21). doi:10.3390/cancers18213573

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.